MX392126B - Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo - Google Patents
Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismoInfo
- Publication number
- MX392126B MX392126B MX2020003805A MX2020003805A MX392126B MX 392126 B MX392126 B MX 392126B MX 2020003805 A MX2020003805 A MX 2020003805A MX 2020003805 A MX2020003805 A MX 2020003805A MX 392126 B MX392126 B MX 392126B
- Authority
- MX
- Mexico
- Prior art keywords
- glatiramer
- acceptable salt
- pharmacologically acceptable
- deposit systems
- effective amount
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title abstract 3
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 title abstract 2
- 229940042385 glatiramer Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 abstract 1
- 229960003776 glatiramer acetate Drugs 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Epoxy Resins (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29192810P | 2010-01-04 | 2010-01-04 | |
| PCT/IL2010/000679 WO2011080733A1 (en) | 2010-01-04 | 2010-08-19 | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020003805A MX2020003805A (es) | 2022-05-05 |
| MX392126B true MX392126B (es) | 2025-03-21 |
Family
ID=44226217
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003805A MX392126B (es) | 2010-01-04 | 2010-08-19 | Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo |
| MX2012007760A MX349162B (es) | 2010-01-04 | 2010-08-19 | Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo. |
| MX2017009179A MX374215B (es) | 2010-01-04 | 2010-08-19 | Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007760A MX349162B (es) | 2010-01-04 | 2010-08-19 | Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo. |
| MX2017009179A MX374215B (es) | 2010-01-04 | 2010-08-19 | Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo |
Country Status (21)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
| WO2013038399A1 (en) | 2011-09-18 | 2013-03-21 | Bio Plasmar Ltd | Bio-degradable compositions and use thereof |
| WO2014128079A1 (en) * | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| MX2016001422A (es) * | 2013-07-29 | 2016-10-05 | Aizant Drug Res Solutions Pvt Ltd | Composicion farmaceutica de fingolimod. |
| WO2015100370A2 (en) * | 2013-12-23 | 2015-07-02 | Kineta One, Llc | Sustained release depot formulations of therapeutic proteins, and uses thereof |
| WO2015140790A1 (en) | 2014-03-17 | 2015-09-24 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| WO2017053346A1 (en) | 2015-09-21 | 2017-03-30 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
| US12161688B2 (en) | 2016-06-30 | 2024-12-10 | Mapi Pharma Ltd | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells |
| JP7232752B2 (ja) * | 2016-08-28 | 2023-03-03 | マピ ファーマ リミテッド | 酢酸グラチラマーを含有する微小粒子を調製する方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| JP7193448B2 (ja) * | 2016-08-31 | 2022-12-20 | マピ ファーマ リミテッド | 酢酸グラチラマーを含むデポシステム |
| JP6712003B2 (ja) * | 2016-10-28 | 2020-06-17 | スパインセラＳｐｉｎｅｔｈｅｒａ | 医薬組成物及びその使用 |
| WO2018172850A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
| IL316573A (en) * | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| IL269893B2 (en) | 2017-05-15 | 2023-10-01 | Stem Cell Medicine Ltd | Treatment of multiple sclerosis with adipose-derived stem cells |
| CA3062964C (en) * | 2017-05-15 | 2024-11-12 | Mapi Pharma Ltd. | TREATMENT OF MULTIPLE SCLEROSIS WITH A LONG-ACTING GLATIRAMER AND ADIPE-DERIVED STEM CELLS |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
| WO2022003662A1 (en) * | 2020-06-29 | 2022-01-06 | Mapi Pharma Ltd. | Low burst-release liraglutide depot systems |
| JP2023550545A (ja) * | 2020-11-02 | 2023-12-01 | シムハ・アイエル－１８・インコーポレイテッド | インターロイキン－１８バリアントおよび使用の方法 |
| WO2022153262A1 (en) | 2021-01-18 | 2022-07-21 | Anton Frenkel | Pharmaceutical dosage form |
| US20220296524A1 (en) * | 2021-01-29 | 2022-09-22 | Tionlab Therapeutics | Initial burst release controlled depot composition and a method thereof |
| US11865213B2 (en) | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| CA3227324A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
| WO2023170493A1 (en) * | 2022-03-07 | 2023-09-14 | Hadidi Naghmeh | Drug delivery using a parenteral pharmaceutical composition |
| EP4583844A1 (en) * | 2022-09-06 | 2025-07-16 | Regents of the University of Michigan | Biodegradable polymeric particles for delivery of positively charged therapeutic agents |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5858964A (en) | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
| IT1276690B1 (it) | 1995-06-09 | 1997-11-03 | Ira Srl | Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| EP1128839A4 (en) | 1998-11-12 | 2002-10-09 | Yeda Res & Dev | PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD |
| DE60112718T2 (de) | 2000-01-20 | 2006-06-29 | Yeda Research And Development Co., Ltd. | Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie |
| DE60116467T2 (de) | 2000-06-07 | 2006-11-02 | Yeda Research And Development Co., Ltd. | Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat |
| US6835711B2 (en) | 2001-06-28 | 2004-12-28 | Yeda Research And Development Co. Ltd. | Use of poly-Glu,Tyr for neuroprotective therapy |
| IL159715A0 (en) * | 2001-07-10 | 2004-06-20 | Teva Pharma | Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| DE02800437T1 (de) | 2001-10-03 | 2004-11-11 | The President And Fellows Of Harvard College, Cambridge | Copolymere zur unterdrückung von autoimmunkrankheiten und anwendungsverfahren |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| CN1398584A (zh) * | 2002-07-15 | 2003-02-26 | 裴福兴 | 一种bFGF－PLGA缓释微球及其制备方法和用途 |
| US20050142205A1 (en) * | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| KR101137785B1 (ko) * | 2003-07-18 | 2012-04-25 | 백스터 인터내셔널 인코포레이티드 | 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물 |
| US20060276390A1 (en) * | 2003-07-31 | 2006-12-07 | Yeda Research And Development Co. Ltd. | Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| NZ546379A (en) * | 2003-10-31 | 2010-04-30 | Teva Pharma | Nanoparticles for drug delivery |
| KR101242486B1 (ko) | 2004-01-12 | 2013-03-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 장기 전달을 위한 제형 및 그의 이용 방법 |
| NZ549731A (en) | 2004-03-01 | 2009-11-27 | Peptimmune Inc | Methods and compositions for treatment of autoimmune diseases |
| US7655221B2 (en) * | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| US7517856B2 (en) | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
| WO2008075365A1 (en) | 2006-12-20 | 2008-06-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for treatment of age related degeneration of the retina |
| PL2187882T3 (pl) * | 2007-07-11 | 2013-05-31 | Medicinova Inc | Leczenie postępującej choroby neurodegeneracyjnej ibudilastem |
| WO2010011879A2 (en) * | 2008-07-25 | 2010-01-28 | The Johns Hopkins University | Methods and compositions for treating and preventing autoimmune diseases |
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
-
2010
- 2010-08-19 DK DK18205308.2T patent/DK3536333T3/da active
- 2010-08-19 US US13/258,808 patent/US8796226B2/en active Active
- 2010-08-19 ES ES18205308T patent/ES2928900T3/es active Active
- 2010-08-19 BR BR112012016459A patent/BR112012016459B1/pt active IP Right Grant
- 2010-08-19 MX MX2020003805A patent/MX392126B/es unknown
- 2010-08-19 JP JP2012546553A patent/JP5916622B2/ja active Active
- 2010-08-19 LT LTEP10840699.2T patent/LT2398488T/lt unknown
- 2010-08-19 SI SI201031811T patent/SI2398488T1/sl unknown
- 2010-08-19 PL PL10840699T patent/PL2398488T3/pl unknown
- 2010-08-19 WO PCT/IL2010/000679 patent/WO2011080733A1/en not_active Ceased
- 2010-08-19 HR HRP20221208TT patent/HRP20221208T1/hr unknown
- 2010-08-19 PL PL18205308.2T patent/PL3536333T3/pl unknown
- 2010-08-19 DK DK10840699.2T patent/DK2398488T3/en active
- 2010-08-19 PT PT10840699T patent/PT2398488T/pt unknown
- 2010-08-19 CN CN201710417220.8A patent/CN107184954A/zh active Pending
- 2010-08-19 HR HRP20182076TT patent/HRP20182076T1/hr unknown
- 2010-08-19 PT PT182053082T patent/PT3536333T/pt unknown
- 2010-08-19 SM SM20220422T patent/SMT202200422T1/it unknown
- 2010-08-19 ES ES10840699T patent/ES2699692T3/es active Active
- 2010-08-19 LT LTEP18205308.2T patent/LT3536333T/lt unknown
- 2010-08-19 CN CN2010800606327A patent/CN102686235A/zh active Pending
- 2010-08-19 AU AU2010337822A patent/AU2010337822B2/en active Active
- 2010-08-19 TR TR2018/18858T patent/TR201818858T4/tr unknown
- 2010-08-19 SM SM20190020T patent/SMT201900020T1/it unknown
- 2010-08-19 MX MX2012007760A patent/MX349162B/es active IP Right Grant
- 2010-08-19 CA CA2784394A patent/CA2784394C/en active Active
- 2010-08-19 HU HUE18205308A patent/HUE060304T2/hu unknown
- 2010-08-19 HU HUE10840699A patent/HUE040390T2/hu unknown
- 2010-08-19 MX MX2017009179A patent/MX374215B/es unknown
- 2010-08-19 CN CN201711120362.4A patent/CN107661490B/zh active Active
- 2010-08-19 EP EP10840699.2A patent/EP2398488B1/en active Active
- 2010-08-19 EP EP18205308.2A patent/EP3536333B1/en active Active
-
2015
- 2015-11-20 JP JP2015227317A patent/JP2016074696A/ja not_active Withdrawn
-
2018
- 2018-03-06 HK HK18103162.6A patent/HK1244430A1/zh unknown
- 2018-12-07 CY CY181101307T patent/CY1120975T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX374215B (es) | Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo | |
| UA108885C2 (uk) | Композиція рисперидону для ін'єкційної депо-форми | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| UA111599C2 (uk) | Композиція каспофунгіну | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| CL2013003406A1 (es) | Compuestos derivados de dolastatina unidos a aminoacidos no naturales; procedimiento de preparacion; composiciones farmaceuticas, útiles en el tratamiento del cancer de mamas. | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| BR112016011949A8 (pt) | composto, composição farmacêutica, e, uso dos mesmos | |
| EA201300860A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
| MX2018005340A (es) | Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos. | |
| EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| NZ630888A (en) | Antibody drug conjugate (adc) purification | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| IN2014MN00333A (cg-RX-API-DMAC7.html) | ||
| MX2011000255A (es) | Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer. | |
| WO2012168885A9 (en) | Bisacodyl and its analogues as drugs for use in the treatment of cancer | |
| AR092993A1 (es) | Laquinimod para reducir el daño talamico en la esclerosis multiple | |
| EA201171043A1 (ru) | Композиции и способы длительной терапии с применением аминопиридинов | |
| MX2016004257A (es) | Composiciones oftalmicas basadas en epinefrina para la administracion intraocular y metodos para su frabricacion. | |
| NZ735777A (en) | Methods and compositions to inhibit symptoms associated with veisalgia | |
| MX336278B (es) | Composiciones y metodos para la prevencion y el tratamiento de heridas. | |
| WO2015057893A3 (en) | Compositions and the use of a fibrinogen binding motif present in efb and coa for vaccination against staphylococcus aureus and for drug delivery | |
| DOP2013000206A (es) | Inhibidores de la peptido desformilasa | |
| EA201991531A1 (ru) | Способы лечения композициями линаклотида с отсроченным высвобождением |